linjc16/ctgov huggingface dataset:
Bearing nsPVA Embolization for Uterine Artery Embolization

Study Overview
=================
Brief Summary
-----------------
This is a prospective, multicenter, observational, post-market clinical follow-up study in subjects treated with Bearing nsPVA Embolization Particles for uterine fibroid embolization. Data collection will include safety and performance outcome relating to the use of Bearing nsPVA, through 6 months.

Official Title
-----------------
Prospective, Multi-Center Study Using Bearing nsPVA Embolization Particles for the Treatment of uTErine fibRoids With Uterine Artery Embolization

Conditions
-----------------
Uterine Fibroid

Intervention / Treatment
-----------------
* Device: Bearing nsPVA


Participation Criteria
=================
Eligibility Criteria
-----------------
Inclusion Criteria: Adult women ≥ 18 years old at the time of enrollment. Subject has symptomatic uterine fibroid(s), suitable to embolization. Subject provides written informed consent. Exclusion Criteria: Subject is pregnant. Subject has suspected pelvic inflammatory disease or any other pelvic infection. Subject has any malignancy of the pelvic region, (e.g., endometrial neoplasia).

Ages Eligible for Study
-----------------
Minimum Age: 18 Years

Sexes Eligible for Study
-----------------
Female

Accepts Healthy Volunteers
-----------------
No

Study Plan
=================
How is the study designed?
-----------------

Arms and Interventions

| Intervention/Treatment |
| --- |
|Device: Bearing nsPVA|Bearing nsPVA Embolization Particles are irregularly-shaped, biocompatible, hydrophilic, nonresorbable particles produced from polyvinyl alcohol. These embolization particles are intended to provide vascular occlusion or reduction of blood flow within target vessels upon selective placement through a variety of catheters. Bearing nsPVA Embolization Particles are used for the embolization of symptomatic (leiomyoma uteri) uterine fibroids.|

What is the study measuring?
-----------------
Primary Outcome Measures

| Outcome Measure | Measure Description | Time Frame |
| --- | --- | --- |
| Primary Safety | The primary safety endpoint will be the absence of serious device-related adverse events (AEs) through 30 days. | 30 days | 
| Primary Effectiveness | The primary effectiveness endpoint will be clinical success defined as ≥ 50% improvement in the Uterine Fibroid Symptom and Quality of Life (UFS-QoL) Symptom Severity subscale at 6 months as compared to baseline. | 6 months |
IL6 on Umbilical Cord (Evaluation of IL-6 Levels on Umbilical Cord)

Study Overview
=================
Brief Summary
-----------------
Fetal inflammatory response syndrome (FIRS) is a major cause of non-hypoxic fetal intrapartum injury. One of the most common determinants of FIRS during labor is the exposure to an ongoing intra-amniotic infectious agent as in the event of a chorioamnionitis. Interleuchine-6 (IL-6) is considered a reliable hallmark of FIRS. No specific fetal heart rate pattern for the diagnosis of FIRS have been described so far at intrapartum Cardiotocography (CTG). The aim the present study is to investigate the correlation between intrapartum CTG findings and IL-6 levels on the arterial cord.

Detailed Description
-----------------
The labor will be managed according to the local protocol and 5mL of blood will collected from the umbilical artery soon after birth to determine the IL-6 values. CardioTocography (CTG) traces will be retrospectively reviewed by two expert operators that will be blinded to the IL-6 results and will categorize them as inflammatory or not inflammatory. Inflammatory pattern will be defined in presence of 1) inappropriately high FHR for the given gestational age and/or 2) an increase >10% compared with the FHR baseline values at admission without preceding deceleration with/without reduced variability or absent cycling. The association between CTG findings as the umbilical levels of IL6 will be analyzed.

Official Title
-----------------
Evaluation of IL-6 Levels on Umbilical Cord

Conditions
-----------------
Intrauterine Infection, Fetus Disorder

Participation Criteria
=================
Eligibility Criteria
-----------------
Inclusion Criteria: singleton pregnancies at term submitted to a continuous CTG tracing during labor Exclusion Criteria:elective Cesarean Delivery, maternal tachycardia or pyrexia >38°C, drugs assumption -

Ages Eligible for Study
-----------------
Minimum Age: 18 Years
Maximum Age: 50 Years

Sexes Eligible for Study
-----------------
Female

Accepts Healthy Volunteers
-----------------
No

Study Plan
=================
How is the study designed?
-----------------
What is the study measuring?
-----------------
Primary Outcome Measures

| Outcome Measure | Measure Description | Time Frame |
| --- | --- | --- |
| IL6 Levels | correlation between intrapartum CTG findings and IL-6 levels on the arterial cord | IL6 will be measured on the umbilical blood sampled within 5 minutes after birth |
Recording and Evaluating Preoperative Malnutrition in Electively Scheduled Adult Surgical Patients With the GLIM Criteria (GLIM-study)

Study Overview
=================
Brief Summary
-----------------
Data about the prevalence of preoperative malnutrition according to all the five GLIM criteria among the broad range of surgical patients are lacking. The current study will investigate the prevalence of malnutrition according to all of the five GLIM criteria in electively planned surgical patients in a large academic hospital, the Amsterdam University Medical Centres, location AMC, where over 11.000 patients are operated on yearly.

Official Title
-----------------
Recording and Evaluating Preoperative Malnutrition in Electively Scheduled Adult Surgical Patients With the GLIM Criteria (GLIM-study)

Conditions
-----------------
Malnutrition

Intervention / Treatment
-----------------
* Other: prevalence of preoperative malnutrition


Participation Criteria
=================
Eligibility Criteria
-----------------
Inclusion Criteria: Patients scheduled for elective surgery at the operating theatres of the AUMC, location AMC Patients ≥ 18 years Dutch speaking Willing and able to sign consent for re-use of care data The study can be combined with other studies Exclusion Criteria: Patients < 18 years Not speaking Dutch Patients who do not sign consent for re-use of care data

Ages Eligible for Study
-----------------
Minimum Age: 18 Years

Sexes Eligible for Study
-----------------
All

Study Plan
=================
How is the study designed?
-----------------

Arms and Interventions

| Intervention/Treatment |
| --- |
|Other: prevalence of preoperative malnutrition|prevalence of preoperative malnutrition|

What is the study measuring?
-----------------
Primary Outcome Measures

| Outcome Measure | Measure Description | Time Frame |
| --- | --- | --- |
| prevalence of preoperative malnutrition | To study the prevalence of preoperative malnutrition according to the GLIM criteria in electively scheduled adult surgical patients. | preoperative |
A Retrospective Study for Multiple Endocrine Neoplasia

Study Overview
=================
Brief Summary
-----------------
Retrospectively review the clinical characteristics of patients with multiple endocrine neoplasia type I in National Taiwan University Hospital.

Detailed Description
-----------------
The investigators will retrospectively review the clinical characteristics of patients with multiple endocrine neoplasia type I in National Taiwan University Hospital.

Official Title
-----------------
A Retrospective Study for Multiple Endocrine Neoplasia

Conditions
-----------------
Multiple Endocrine Neoplasia

Intervention / Treatment
-----------------
* Other: no intervention


Participation Criteria
=================
Eligibility Criteria
-----------------
Inclusion Criteria: Patients with multiple endocrine neoplasia Exclusion Criteria: Patients younger than 18 years old

Ages Eligible for Study
-----------------
Minimum Age: 18 Years
Maximum Age: 99 Years

Sexes Eligible for Study
-----------------
All

Accepts Healthy Volunteers
-----------------
No

Study Plan
=================
How is the study designed?
-----------------

Arms and Interventions

| Participant Group/Arm | Intervention/Treatment |
| --- | --- |
| multiple endocrine neoplasia<br>patients with multiple endocrine neoplasia | Other: no intervention<br>* No intervention, only observation<br>|

What is the study measuring?
-----------------
Primary Outcome Measures

| Outcome Measure | Measure Description | Time Frame |
| --- | --- | --- |
| Number or endocrine organs involved | The number of endocrine organs involved in MEN patients | 2023/2/14-2033/2/14 |
FirmTech User Research Trial

Study Overview
=================
Brief Summary
-----------------
The objective of this study is to see whether a home-use penile constriction device, Firmtech Tech Ring, can be determined to be superior to the Giddy device through evaluation of Leikert scale scores to assess ease of use and participant comfort and satisfaction with erectile quality with these devices. The primary outcome will be the satisfaction with use of the device as assessed through the Leikert scores. The other outcomes will be secondary.

Official Title
-----------------
FirmTech User Research Trial

Conditions
-----------------
Erectile Function

Intervention / Treatment
-----------------
* Other: FirmTech Tech Ring
* Other: Giddy Penile Constriction Ring


Participation Criteria
=================
Eligibility Criteria
-----------------
Inclusion Criteria: All English-speaking participants > 18 years old recruited through social media. Physically and emotionally capable of engaging in sexual activity with at least one attempt per week of masturbation or sexual intercourse Exclusion Criteria: Men who cannot understand English. Men with a prior or current penile implant. Transgender or non-binary individuals Men diagnosed with a hidden or buried penis. Investigator's impression of expected poor participant compliance or anatomic inadequacy (penile size/girth) Any psychiatric disorder, which, in the opinion of the investigator, would prohibit participation. Coagulopathy or other blood disorder which the investigator determines would affect the participant's participation in the trial. Any tumor in the pelvic or penile region within the last 3 years Men with an active caregiver who are unable to live independently. Men who the provider is concerned would be at high risk for non-healing wounds of the penis. Participants with sensory disorders like sensory processing disorder, sensory integration dysfunction disorder, neuropathies, etc.

Ages Eligible for Study
-----------------
Minimum Age: 18 Years
Maximum Age: 70 Years

Sexes Eligible for Study
-----------------
Male

Study Plan
=================
How is the study designed?
-----------------

Arms and Interventions

| Intervention/Treatment |
| --- |
|Other: FirmTech Tech Ring|Participants will utilize the FirmTech Tech Ring at least twice during a two-week time period and complete a survey|
|Other: Giddy Penile Constriction Ring|Participants will utilize the Giddy Penile Constriction at least twice during a two-week time period and complete a survey|

What is the study measuring?
-----------------
Primary Outcome Measures

| Outcome Measure | Measure Description | Time Frame |
| --- | --- | --- |
| Device satisfaction via Leikert scores | A survey will be completed for each device after utilization | 2 weeks after receiving device |
Clinical Efficacy of Axillary Block in Cervical Radiculopathy

Study Overview
=================
Brief Summary
-----------------
The primary endpoint of this study was to compare the clinical efficacy of axillary block in patients of cervical radiculopathy using 2 volumes of local anesthetics.

Detailed Description
-----------------
The interscalene brachial plexus block is an effective intervention for reducing postoperative pain but is related to side effects, Suprascapular nerve block and a block of the axillary nerve have been introduced as alternatives to the interscalene brachial plexus for the control of postoperative pain. Previous study demonstrated new method of axillary block using interfascial plane injection guided by ultrasoud. Axillary block has been used widely for the relief of postoperative arm pain. Recent study deomonstrated good pain relief when ultrasound guided interfascial plane injection was performed in patients with cervical radiuculopathy. There is no study showing clinical efficacy of interfascial plane injection of axillary block in patients of cervical radiculopathy.

Official Title
-----------------
Comparison of Clinical Efficacy of Axillary Block in Patients of Cervical Radiculopathy

Conditions
-----------------
Pain, Chronic

Intervention / Treatment
-----------------
* Procedure: axillary block guided by ultrasound


Participation Criteria
=================
Eligibility Criteria
-----------------
Inclusion Criteria: Cervical foraminal stenosis Cervical central stenosis Cervical disc herniation Cervical spondylolisthesis Prominent arm pain rather than neck pain Exclusion Criteria: Infection Pregnancy allergy to local anesthetic agents previous cervical spine surgery Prominent neck pain rather than arm pain

Ages Eligible for Study
-----------------
Minimum Age: 20 Years
Maximum Age: 80 Years

Sexes Eligible for Study
-----------------
All

Accepts Healthy Volunteers
-----------------
No

Study Plan
=================
How is the study designed?
-----------------

Design Details

Primary Purpose: Treatment
Allocation: Randomized
Intervention Model: Parallel Assignment
Masking: Double


Arms and Interventions

| Participant Group/Arm | Intervention/Treatment |
| --- | --- |
| Active Comparator: 5ml axillary block group<br>interfascial plane axillary block group using 5 ml local anesthetics | Procedure: axillary block guided by ultrasound<br>* axillary block using local anesthetics<br>|
| Active Comparator: 10ml axillary block group<br>interfascial plane axillary block group using 10 ml local anesthetics | Procedure: axillary block guided by ultrasound<br>* axillary block using local anesthetics<br>|

What is the study measuring?
-----------------
Primary Outcome Measures

| Outcome Measure | Measure Description | Time Frame |
| --- | --- | --- |
| Numerical rating scale changes among 4 time periods | Numerical rating scale changes among 4 time periods | baseline, 2 weeks after injection, 4 weeks after injection, 8 weeks after injection | 
| Neck disability injex changes between 2 time periods | Neck disability injex changes between 2 time periods | baseline, 8 weeks after injection |
Neurally Adjusted Ventilatory Assist for Weaning From Invasive Mechanical Ventilation in Critically Ill Children

Study Overview
=================
Brief Summary
-----------------
The goal of this clinical trial is to compare weaning from mechanical ventilation in critically ill children. The main questions it aims to answer are: Will weaning with neurally adjusted ventilatory assist (NAVA) mode ventilation result in shorter ventilator day than synchronised intermittent mandatory ventilation (SIMV) mode? Will weaning with NAVA mode ventilation result in shorter paediatric intensive care unit (PICU) length of stay than SIMV mode? Participants will be randomised to NAVA or SIMV group for weaning from mechanical ventilation, then PICU outcomes from both groups will be collected, analysed and compared.

Official Title
-----------------
Neurally Adjusted Ventilatory Assist for Weaning From Invasive Mechanical Ventilation in Critically Ill Children: A Randomised Control Trial

Conditions
-----------------
Mechanical Ventilator Weaning, Critically Ill, Mechanical Ventilation, Neurally Adjusted Ventilatory Assist

Intervention / Treatment
-----------------
* Procedure: NAVA


Participation Criteria
=================
Eligibility Criteria
-----------------
Inclusion Criteria: all critically ill children admitted to PICU Exclusion Criteria: failure to obtain informed consent

Ages Eligible for Study
-----------------
Minimum Age: 1 Month
Maximum Age: 18 Years

Sexes Eligible for Study
-----------------
All

Accepts Healthy Volunteers
-----------------
Accepts Healthy Volunteers

Study Plan
=================
How is the study designed?
-----------------

Design Details

Primary Purpose: Supportive Care
Allocation: Randomized
Intervention Model: Parallel Assignment
Masking: None (Open Label)


Arms and Interventions

| Participant Group/Arm | Intervention/Treatment |
| --- | --- |
| Experimental: NAVA<br> | Procedure: NAVA<br>* weaning from mechanical ventilator using neurally adjusted ventilatory assist<br>|
| No Intervention: SIMV<br> | |

What is the study measuring?
-----------------
Primary Outcome Measures

| Outcome Measure | Measure Description | Time Frame |
| --- | --- | --- |
| ventilator day | number of days patients receive mechanical ventilation | immediately after extubation | 
| PICU length of stay | number of days patients remain in PICU | immediately after PICU discharge | 

Secondary Outcome Measures

| Outcome Measure | Measure Description | Time Frame |
| --- | --- | --- |
| asynchrony index | asynchronous breaths divided by total breaths in 20 minutes | 20-minute period randomly captured from the day of extubation |
Foot Disorders in X-linked Hypophosphatemia

Study Overview
=================
Brief Summary
-----------------
This study aimed to characterize foot pathologies using X-rays and clinical examination and assess related outcome scores in adolescents and adults with X-linked Hypophophatemia

Detailed Description
-----------------
A single center, cross-sectional analysis of adolescent and adult patients with XLH with and without previous surgical intervention was performed at the Orthopaedic Hospital Speising, Vienna, Austria. Clinical examination, quality of life questionnaires and radiographic data of foot x-rays in standing position were collected. Radiographic evaluation was performed to analyze foot deformity as well as signs of osteoarthritis at the foot.

Official Title
-----------------
Mid- and Forefoot Disorders in Adolescents and Adults With X-linked Hypophosphatemia

Conditions
-----------------
X-linked Hypophosphatemia

Intervention / Treatment
-----------------
* Radiation: Foot X rays
* Diagnostic Test: Clinical examination + scores


Participation Criteria
=================
Eligibility Criteria
-----------------
Inclusion Criteria: - Patients with confirmed XLH, ≥ 16 years were invited to participate in this study Exclusion Criteria: Exclusion criteria were other forms of hypophosphatemia, pregnancy and recent lower limb surgery within 3 months.

Ages Eligible for Study
-----------------
Minimum Age: 16 Years
Maximum Age: 100 Years

Sexes Eligible for Study
-----------------
All

Accepts Healthy Volunteers
-----------------
No

Study Plan
=================
How is the study designed?
-----------------

Arms and Interventions

| Intervention/Treatment |
| --- |
|Radiation: Foot X rays|Radiographs of ankle and foot anteroposterior/dorsoplantar were taken in standing position with a centralized beam on the ankle joint.|
|Diagnostic Test: Clinical examination + scores|The American Orthopedic Foot and Ankle Society Score (AOFAS- midfoot section and 1st Forefoot ray, Forefoot ray 2-5) and the foot function index (FFI) were assessed|

What is the study measuring?
-----------------
Primary Outcome Measures

| Outcome Measure | Measure Description | Time Frame |
| --- | --- | --- |
| Number of feet with signs of osteoarthritis | radiographic signs of osteoarthritis at the foot joints | baseline | 

 Terms related to the study
=================
Keywords Provided by Centre Hospitalier Valida
-----------------
foot and ankle
A 6-month Follow-up Study of Patients With Severe Fever With Thrombocytopenia Syndrome

Study Overview
=================
Brief Summary
-----------------
This is a multi-center, retrospective clinical study to analyze the clinical features, laboratory indicators, imaging changes, treatment options and long-term prognosis in patients with sever fever with thrombocytopenia syndrome. All hospitalized patients with sever fever with thrombocytopenia diagnosed between 2016 and 2022 were included from the electronic medical record system of 8 centers, and demographics, hospitalization information, clinical information, laboratory or imaging examinations, treatment options, and outcomes were collected.

Official Title
-----------------
A 6-month Follow-up Study of Patients With Severe Fever With Thrombocytopenia Syndrome

Conditions
-----------------
Severe Fever With Thrombocytopenia Syndrome

Participation Criteria
=================
Eligibility Criteria
-----------------
Inclusion Criteria: Age and gender are not limited; Hospitalized patients diagnosed with severe fever with thrombocytopenia syndrome have at least one of the following laboratory test results: serum severe fever with thrombocytopenia syndrome bunyavirus (SFTSV)-specific IgM antibody positive or IgG antibody level increased more than 4 times; or positive for SFTSV RNA; or positive for SFTSV nucleic acid detected by real-time fluorescent quantitative RT-PCR; or SFTSV isolated from case specimens. Exclusion Criteria: Patients who were found to be positive for other tick-borne pathogens by PCR analysis of blood samples in the acute phase; It is difficult to conduct outpatient follow-up due to mental disorders, dementia, combined diseases such as osteoarthropathy, stroke, pulmonary embolism, etc. that lead to inability to move freely; No outpatient follow-up visit after discharge, and repeated confirmation by phone call still unable to get in touch; Due to living in other places, nursing homes, welfare homes, unable to participate in outpatient follow-up after making an appointment by phone; Currently participating in clinical trials of other drugs or medical devices; The researchers think it is not suitable for inclusion.
Sexes Eligible for Study
-----------------
All

Accepts Healthy Volunteers
-----------------
No

Study Plan
=================
How is the study designed?
-----------------
What is the study measuring?
-----------------
Primary Outcome Measures

| Outcome Measure | Measure Description | Time Frame |
| --- | --- | --- |
| The presense of clinical symptoms of patients at 3 months and 6 months after discharge | The number and severity of clinical symptoms of patients. | 3 months,6 months | 

Secondary Outcome Measures

| Outcome Measure | Measure Description | Time Frame |
| --- | --- | --- |
| Number of participants with different outcome of disease | Number of participants who experience these events: discharge with improvement death automatic discharge | 6 months |